CLAIMS

1. Use of a fixed-dose combination of zibotentan and dapagliflozin for the manufacture of a medicament for the treatment of chronic kidney disease in a human patient who has:

   a) a urinary protein to creatine ratio (UPCR) of greater than 1 g/g, or

   b) a urinary albumin to creatine ratio (UACR) of greater than 700 mg/g,

   wherein the fixed-dose combination comprises:

   i) zibotentan at a dose of 0.25 mg and dapagliflozin at a dose of 10 mg; or

   ii) zibotentan at a dose of 0.75 mg and dapagliflozin at a dose of 10 mg.

2. The use according to claim 1, wherein the fixed-dose combination comprising zibotentan at a dose of 0.25 mg and dapagliflozin at a dose of 10 mg.

3. The use according to claim 1, wherein the fixed-dose combination comprising zibotentan at a dose of 0.75 mg and dapagliflozin at a dose of 10 mg.

4. The use according to claim 1, wherein the patient has an estimated glomerular filtration rate (eGFR) of 20-90 mL/min/1.73 m^2.

5. The use according to claim 2, wherein the patient that has an eGFR that is < 45 mL/min/1.73 m^2.

6. The use according to claim 3, wherein the patient that has an eGFR that is ≥ 45 mL/min/1.73 m^2.

7. The use according to claim 1, wherein the zibotentan is to be administered at a dose of 0.25 mg and the dapagliflozin is to be administered at a dose of 10 mg when the patient has an eGFR that is < 45 mL/min/1.73 m^2, and the zibotentan is to be administered at a dose of 0.75 mg and the dapagliflozin is to be administered at a dose of 10 mg when the patient has an eGFR that is ≥ 45 mL/min/1.73 m^2.

8. The use according to any one of the preceding claims, wherein the patient has a UPCR of 1-1.3 g/g.

9. The use according to any one of the preceding claims, wherein the patient has a UACR of 700-900 mg/g.

10. The use according to any one of the preceding claims, wherein the patient has a UPCR of 1-1.3 g/g and a UACR of 700-900 mg/g.

11. The use according to any one of the preceding claims, wherein the patient is naïve to a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

12. The use according to any one of the preceding claims, wherein the fixed dose combination is for once-daily administration.

13. The use according to any one of the preceding claims, wherein the medicament is for the treatment of Alport syndrome.

14. The use according to any one of claims 1 to 12, wherein the medicament is for the treatment of a patient with biopsy confirmed IgA nephropathy.